...
首页> 外文期刊>Cancers >EBNA1: Oncogenic Activity, Immune Evasion and Biochemical Functions Provide Targets for Novel Therapeutic Strategies against Epstein-Barr Virus- Associated Cancers
【24h】

EBNA1: Oncogenic Activity, Immune Evasion and Biochemical Functions Provide Targets for Novel Therapeutic Strategies against Epstein-Barr Virus- Associated Cancers

机译:EBNA1:致癌活性,免疫逃逸和生化功能为针对爱泼斯坦-巴尔病毒相关癌症的新型治疗策略提供目标。

获取原文
   

获取外文期刊封面封底 >>

       

摘要

The presence of the Epstein-Barr virus (EBV)-encoded nuclear antigen-1 (EBNA1) protein in all EBV-carrying tumours constitutes a marker that distinguishes the virus-associated cancer cells from normal cells and thereby offers opportunities for targeted therapeutic intervention. EBNA1 is essential for viral genome maintenance and also for controlling viral gene expression and without EBNA1, the virus cannot persist. EBNA1 itself has been linked to cell transformation but the underlying mechanism of its oncogenic activity has been unclear. However, recent data are starting to shed light on its growth-promoting pathways, suggesting that targeting EBNA1 can have a direct growth suppressing effect. In order to carry out its tasks, EBNA1 interacts with cellular factors and these interactions are potential therapeutic targets, where the aim would be to cripple the virus and thereby rid the tumour cells of any oncogenic activity related to the virus. Another strategy to target EBNA1 is to interfere with its expression. Controlling the rate of EBNA1 synthesis is critical for the virus to maintain a sufficient level to support viral functions, while at the same time, restricting expression is equally important to prevent the immune system from detecting and destroying EBNA1-positive cells. To achieve this balance EBNA1 has evolved a unique repeat sequence of glycines and alanines that controls its own rate of mRNA translation. As the underlying molecular mechanisms for how this repeat suppresses its own rate of synthesis in cis are starting to be better understood, new therapeutic strategies are emerging that aim to modulate the translation of the EBNA1 mRNA. If translation is induced, it could increase the amount of EBNA1-derived antigenic peptides that are presented to the major histocompatibility (MHC) class I pathway and thus, make EBV-carrying cancers better targets for the immune system. If translation is further suppressed, this would provide another means to cripple the virus.
机译:在所有携带EBV的肿瘤中均存在爱泼斯坦-巴尔病毒(EBV)编码的核抗原1(EBNA1)蛋白,该标志物可将与病毒相关的癌细胞与正常细胞区分开,从而为靶向治疗提供了机会。 EBNA1对维持病毒基因组以及控制病毒基因表达至关重要,如果没有EBNA1,病毒将无法持久。 EBNA1本身与细胞转化有关,但其致癌活性的潜在机制尚不清楚。但是,最近的数据开始阐明其促进生长的途径,表明靶向EBNA1可以具有直接的生长抑制作用。为了执行其任务,EBNA1与细胞因子相互作用,这些相互作用是潜在的治疗靶标,其目的是削弱病毒,从而使肿瘤细胞摆脱与病毒有关的任何致癌活性。靶向EBNA1的另一种策略是干扰其表达。控制EBNA1合成的速率对于病毒维持足够水平以支持病毒功能至关重要,同时限制表达对防止免疫系统检测和破坏EBNA1阳性细胞同样重要。为了达到这种平衡,EBNA1进化出了独特的甘氨酸和丙氨酸重复序列,可控制其自身的mRNA翻译速率。随着人们越来越了解这种重复序列如何抑制其自身在顺式中的合成速率的潜在分子机制,正在出现新的治疗策略,旨在调节EBNA1 mRNA的翻译。如果翻译被诱导,它可能会增加呈递给主要组织相容性(MHC)I类途径的EBNA1衍生抗原肽的数量,从而使携带EBV的癌症成为免疫系统的更好靶标。如果进一步抑制翻译,这将提供另一种削弱病毒的手段。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号